Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tadao Ishida

Showing results (71-80 of 151) with videos related to

Pageof 16
Sort By:
European Journal of Haematology|November 17, 2019
The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myelomaKiyoshi Okazuka, Tadao Ishida, Junichiro Nashimoto, et al.
Hematological Oncology|January 30, 2024
Prognostic value of the second revision of the international staging system (R2-ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantationTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[IgE-κ type multiple myeloma achieving complete response with novel agents]Tomomi Takei, Tadao Ishida, Masahiro Ikeda, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 4, 2024
[Retrospective analysis of allogeneic hematopoietic stem cell transplantation for multiple myeloma after myeloablative conditioning with 8 Gy of total body irradiation]Nobuhiro Tsukada, Moe Yogo, Kodai Kunisada, et al.
International Journal of Hematology|October 31, 2019
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myelomaIsamu Sugiura, Kenshi Suzuki, Masaki Ri, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 10, 2023
[A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy]Nobuhiro Tsukada, Yuki Oda, Moe Nomura, et al.
Japanese Journal of Clinical Oncology|September 8, 2022
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA studyTadao Ishida, Shigeki Ito, Junji Tanaka, et al.
Annals of Hematology|September 5, 2023
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodiesTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
International Journal of Hematology|April 19, 2024
Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myelomaTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
Acta Haematologica|April 24, 2024
Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple MyelomaTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
Pageof 16

Showing results (71-80 of 151) with videos related to

Sort By:
Pageof 16
European Journal of Haematology|November 17, 2019
The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myelomaKiyoshi Okazuka, Tadao Ishida, Junichiro Nashimoto, et al.
Hematological Oncology|January 30, 2024
Prognostic value of the second revision of the international staging system (R2-ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantationTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[IgE-κ type multiple myeloma achieving complete response with novel agents]Tomomi Takei, Tadao Ishida, Masahiro Ikeda, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 4, 2024
[Retrospective analysis of allogeneic hematopoietic stem cell transplantation for multiple myeloma after myeloablative conditioning with 8 Gy of total body irradiation]Nobuhiro Tsukada, Moe Yogo, Kodai Kunisada, et al.
International Journal of Hematology|October 31, 2019
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myelomaIsamu Sugiura, Kenshi Suzuki, Masaki Ri, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 10, 2023
[A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy]Nobuhiro Tsukada, Yuki Oda, Moe Nomura, et al.
Japanese Journal of Clinical Oncology|September 8, 2022
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA studyTadao Ishida, Shigeki Ito, Junji Tanaka, et al.
Annals of Hematology|September 5, 2023
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodiesTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
International Journal of Hematology|April 19, 2024
Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myelomaTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
Acta Haematologica|April 24, 2024
Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple MyelomaTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.
Pageof 16